Anton Rx Report

Immunoglobulin (IG) has long been a specialized area within pharmacy, yet it continues to influence the broader market. As such, it’s important for pharmaceutical professionals

Yeah, Yeah….The message from the article below is preaching to the choir… but this hymn can’t be sung enough. The central message in this article

The FDA recently approved a new ORAL therapy, Jascayd (nerandomilast) from Boehringer Ingelheim, indicated for idiopathic pulmonary fibrosis (IPF) in adult patients. IPF is a

We’ve often written about white bagging, but today’s spotlight article bears yet another look. A recent NASP survey reinforces what many in specialty pharmacy already know:

The FDA recently approved a ‘2fer’, two biosimilars for the same reference therapy. The two in question are Bosaya and Aukelso, denosumab biosimilars for all indications

Amid what some would call chaos in the halls of the FDA, HHS, etc., some light came shining through recently. The FDA announced a new

Cigna’s Evernorth Health Services is making a bold move in the specialty pharmacy space with a $3.5 billion investment in Shields Health Solutions. The deal

The FDA recently approved a new sub-q therapy, Dawnzera (donidalorsen) from Ionis Pharmaceuticals, Inc. indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in

Manufacturers of rare disease and specialty products in the U.S. face an increasingly intricate distribution landscape. What once looked like a relatively simple path from

The FDA recently approved Papzimeos (zopapogene imadenovec-drba), a new therapy from Precigen Inc., for the treatment of adults with recurrent respiratory papillomatosis (RRP). This marks